Is Wegovy Covered by Insurance? Coverage Guide

Wegovy is one of the most effective weight-management medications brought to market, but its list price of about $1,349 per month (reduced from roughly $1,833 in 2025) makes insurance coverage central for most patients. The question “is Wegovy covered by insurance” has no single answer — commercial plans, Medicare, Medicaid, and employer self-funded plans all handle it differently, and the rules keep shifting. This guide explains what each category covers in 2026, how to verify your own plan, and what to do if your insurance says no. The one constant: you have to check your specific plan, because coverage varies.

The Short Answer

Commercial coverage for obesity has grown steadily since Wegovy’s 2021 FDA approval, but it is far from universal. According to KFF‘s 2025 employer survey, about 43 percent of the largest employers (5,000+ workers) covered a GLP-1 medication for obesity — up from roughly 28 percent a year earlier — while coverage was substantially lower at smaller firms. Medicare Part D still cannot cover Wegovy for weight loss alone, but it can cover it for the drug’s cardiovascular risk-reduction indication, and a new temporary Medicare program adds a low-copay pathway in 2026. Medicaid coverage depends on your state. The bottom line for any individual is that it depends on which plan you have and why Wegovy is being prescribed.

Wegovy has two FDA-approved indications as of 2026: chronic weight management in adults and adolescents who meet BMI criteria, and reduction of cardiovascular risk in adults with established cardiovascular disease who are overweight or have obesity. The cardiovascular indication, approved in March 2024, is what opened the door to limited Medicare coverage.

Commercial Insurance Coverage

Commercial health plans — including employer-sponsored coverage and individual marketplace plans — are the most likely source of Wegovy coverage. Whether your plan includes Wegovy on its formulary depends heavily on your employer’s benefit design and your plan’s pharmacy benefit manager. Large employers are far more likely to cover GLP-1s for obesity than small ones, and even among big employers, fewer than half did so as of KFF’s 2025 data. Coverage tier and prior authorization rules also vary from plan to plan; the major PBMs (CVS Caremark, Express Scripts, and OptumRx) each make their own formulary decisions.

Even when Wegovy is on formulary, prior authorization is almost always required. Typical PA requirements include BMI documentation (often 30 or higher, or 27+ with a weight-related comorbidity), documentation of prior weight-loss attempts (frequently several months of diet and exercise), age verification, and a specific diagnosis code. Approval rates for well-documented submissions are reasonably good, but incomplete paperwork is a common reason for an initial denial — so it pays to make sure your prescriber’s submission is thorough.

Employer Self-Funded Plans

Most large employers use self-funded plans administered by companies like UnitedHealthcare, Aetna, Cigna, or Blue Cross Blue Shield affiliates. These plans have significant flexibility in what they cover, and Wegovy decisions often come down to what the employer is willing to pay. Some large employers explicitly include Wegovy for weight management; others exclude all weight-loss medications from their benefit design, and some have added or dropped GLP-1 coverage year to year as costs are re-evaluated.

Check your plan’s Summary of Benefits and Coverage (SBC) or prescription benefit documentation. Look specifically for sections on “weight management” or “obesity medications.” If Wegovy is excluded, your employer benefits coordinator may be able to tell you whether an exception process exists, though these are not always granted.

Medicare Coverage

Medicare Part D has traditionally excluded Wegovy when prescribed for weight loss. The Medicare statute excludes “drugs used for weight loss” from Part D coverage. This began to change in 2024, when CMS indicated that Wegovy prescribed for cardiovascular risk reduction (following its new FDA indication) could be covered, because that use is not classified solely as weight loss.

In 2026, Part D plans can cover Wegovy when it is prescribed for cardiovascular risk reduction in patients with established cardiovascular disease who are overweight or have obesity. Coverage for weight loss alone remains excluded under the standard Part D rules. Notably, CMS has also launched a temporary Medicare GLP-1 Bridge: from July 1, 2026 through December 31, 2027, eligible Part D beneficiaries may be able to get certain GLP-1 medications approved for weight reduction — including Wegovy — for a flat copay of about $50 per 28- or 30-day supply, with Medicare covering the rest. Eligibility and participating plans matter here, so confirm the details with your plan. The Medicare Part D out-of-pocket cap (about $2,000 per year in 2025, adjusted for 2026) also limits what you pay annually for covered prescriptions. See our Wegovy Medicare guide for a fuller breakdown.

Medicaid Coverage

State Medicaid programs have flexibility in covering weight-loss medications, and a growing minority of states include Wegovy on formulary for specific patient populations. States that have added coverage have generally attached strict requirements — for example, a higher BMI threshold, documented comorbidities, a trial of lifestyle intervention, and prior authorization.

Many states, particularly those with tighter Medicaid budgets, still do not cover Wegovy for weight loss at all. Because states negotiate rebates with Novo Nordisk and revise their preferred drug lists regularly, this picture changes frequently. The reliable move is to check your own state’s Medicaid preferred drug list online (or ask your caseworker) rather than relying on any national summary.

Prior Authorization: How It Works

Even covered plans require prior authorization. Your prescriber submits a form (usually electronically) documenting your BMI, comorbidities, previous weight-loss attempts, and medical necessity. The PBM reviews the submission against the plan’s criteria and issues an approval or denial — typically within 72 hours for standard requests, or 24 hours for expedited ones.

Common denial reasons include missing documentation of prior weight-loss attempts, failure to document comorbidities, a BMI just below the threshold, and plan exclusion of all weight-loss medications. If you’re denied, you have the right to appeal — and appeals succeed more often than many patients expect, especially with additional clinical documentation from your prescriber.

What to Do When Insurance Denies Wegovy

Start by requesting the written denial letter, which must explain the reason. Work with your prescriber to address whatever is missing or contested. First-level appeals are usually handled internally by the plan or PBM and decided within a set window (often around 30 days for standard appeals). If that fails, a second-level or external review may be available.

If appeals don’t succeed, cash-pay options can bring the price well below list. Novo Nordisk’s NovoCare Pharmacy self-pay program has lowered the cost of Wegovy substantially: as of 2026, the standard single-dose pen is priced around $349 per month for self-pay patients (with a lower introductory offer for the first fills for those new to the program), and the oral formulation is priced lower still. Separately, commercially insured patients whose plans cover Wegovy may qualify for the manufacturer savings card, which can reduce out-of-pocket costs to as little as $0 to $25 per fill up to program limits (government beneficiaries are excluded). Prices and offer terms change, so confirm current figures at NovoCare before assuming a number. See our Wegovy cost guide for more savings strategies.

Frequently Asked Questions

Is Wegovy covered by insurance through my employer?

It depends on your employer’s plan design. Coverage of GLP-1s for obesity has grown but is still not universal — KFF found about 43 percent of the largest employers covered one in 2025, with lower rates at smaller firms. Check your plan’s formulary through your prescription benefit portal, or call the member services number on your insurance card, to verify.

Does Medicare cover Wegovy in 2026?

Standard Medicare Part D covers Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease who are overweight or have obesity, but not for weight loss alone. Separately, the temporary Medicare GLP-1 Bridge (July 1, 2026–December 31, 2027) may let eligible Part D members get Wegovy for about a $50 monthly copay. See our does Medicare cover Wegovy guide for details, and confirm eligibility with your plan.

How do I check if my insurance covers Wegovy?

Three ways: log into your prescription benefit portal and search for “Wegovy” or “semaglutide,” call the member services number on your insurance card, or ask your prescriber’s office to run an eligibility check with your insurer before prescribing. Any of these will reflect your plan’s current rules more reliably than a general article.

What is the most common reason Wegovy is denied?

A plan-level exclusion of weight-loss medications is a leading reason. When a plan covers Wegovy in principle, missing documentation of prior weight-loss attempts is a common reason an individual prior-authorization request is denied. Thorough documentation from your prescriber reduces the risk.

Will my insurance cover Wegovy after I appeal?

Appeals succeed a meaningful share of the time when supported by additional clinical documentation, though outcomes vary by plan and situation. Work with your prescriber to submit a clear clinical justification rather than appealing on your own, and keep copies of everything you send.

Your Next Step With Wegovy Insurance

Verify your plan’s current coverage status before assuming anything — check the formulary directly or call member services. If covered, understand the prior authorization requirements and make sure your documentation is complete before submission. If you’re on Medicare, ask specifically about the cardiovascular indication and whether the GLP-1 Bridge applies to you. If not covered, compare the NovoCare self-pay price and the manufacturer savings card against alternative options like Zepbound, which may have different coverage under your plan.

For broader context on insurance coverage of weight-loss medications, the healthcare policy pillar and our what insurance covers Wegovy for weight loss guide cover specific plans in more detail. Understanding the rules before you apply saves time, appeals work, and money.

Sources

• KFF — 2025 Employer Health Benefits Survey (GLP-1 obesity coverage by firm size); analysis of the Medicare GLP-1 Bridge and BALANCE Model
• CMS / Medicare — Part D exclusion of weight-loss-only drugs; coverage for cardiovascular risk reduction; Medicare GLP-1 Bridge ($50 copay, July 1, 2026–Dec 31, 2027); Part D out-of-pocket cap
• Novo Nordisk / NovoCare — Wegovy list price (~$1,349), NovoCare self-pay pricing (~$349/month standard pen, introductory offer) and savings offer for commercially insured patients
• U.S. Food and Drug Administration (FDA) — Wegovy indications, including the March 2024 cardiovascular risk-reduction approval